GAS7 and lung cancer: miR‐181a is related to Gefitinib resistance in lung cancer through an increased expression profile compared with the sensitive models and direct targeting of GAS7; GAS7 is involved in the regulation of AKT/ERK pathways and EMT markers and is downregulated in plasma from Gefitinib‐resistant patients (Ping et al., 2018).